US Stock Market Closed

Dashboard

Agenus, Inc. (AGEN)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

H

Management & Equity

B

Analyst Opinion

B

Leverage & Liquidity

S

Fundamental Variables

H

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes AGEN1884, AGEN2034, INCAGN1876, INCAGN1949, Prophage, AutoSynVax, PhosphoSynVax, and AS-21 Stimulon. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 1994 and is headquartered in Lexington, MA.

CEO

Garo H. Armen

Employees

328

Industry

-

Sector

-

Headquarters

Lexington

Exchange

NASDAQ

Summary Stats

Market Cap

532M

Revenue

310M

Net Income

-18.8M

EPS

-$0.08

Price-to-Earnings

-24.35

Price-to-Book

33.83

Debt-to-Equity

27.08

News

Analyst Ratings

Price targets projected by 2 analysts

High

$8.00

Average

$8.00

Low

$8.00

Ratings calculated by 0 analysts

Buy

0

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.11

Actual

-$0.19 +36.7%

Consensus

-0.3

Report Date

Year Ago

-0.27

Year Ago Change %

Up 29%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites